Residual Risk of Breast Cancer Recurrence Five Years after Adjuvant Systemic Therapy

Breast cancer patients who undergo AST are at risk of late recurrences

Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy
JNCI, Oxford University Press USA journal, source for cancer news and information.

About 1 in 5 breast cancer survivors who have completed 5 years of adjuvant systemic therapy (AST) suffer a recurrence within the 10 years after their treatment, according to a 2008 study published in the Journal of the National Cancer Institute.

Context and Caveats

Prior knowledge:

Adjuvant and neoadjuvant systemic therapy (AST) improves the survival of breast cancer patients, but there is still a risk that the disease will recur years later.

Study design:

Disease recurrence among breast cancer patients who were disease free 5 years after AST (the landmark) was estimated 5 and 10 years after landmark. Multivariable analysis was used to identify factors associated with recurrence.

Contributions:

Rates of recurrence-free survival at 5 years and 10 years after landmark were 89% and 80%, respectively. The risk of recurrence 5 years after therapy increased with tumor stage (stage 1: 7%, stage II: 11%, and stage 3: 13%) and was also associated with tumor grade, hormone receptor status, and endocrine therapy.

Implications:

Breast cancer patients who undergo AST are at risk of late recurrences, and this risk is associated with certain characteristics of the original tumor.

Limitations:

HER2/neu status was not included in the analysis because the data were not available; aromatase inhibitor treatment was not included because too few women received it.

Sources and full study:

Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy, JNCI, June 2008, Vol 100, Issue 16Pp. 1179-1183.

For DES Daughters

2 thoughts on “Residual Risk of Breast Cancer Recurrence Five Years after Adjuvant Systemic Therapy”

Have your say ! Share your views